Literature DB >> 12132896

An ontology for pharmaceutical ligands and its application for in silico screening and library design.

Ansgar Schuffenhauer1, Jürg Zimmermann, Ruedi Stoop, Jan-Jan van der Vyver, Steffano Lecchini, Edgar Jacoby.   

Abstract

Annotation efforts in biosciences have focused in past years mainly on the annotation of genomic sequences. Only very limited effort has been put into annotation schemes for pharmaceutical ligands. Here we propose annotation schemes for the ligands of four major target classes, enzymes, G protein-coupled receptors (GPCRs), nuclear receptors (NRs), and ligand-gated ion channels (LGICs), and outline their usage for in silico screening and combinatorial library design. The proposed schemes cover ligand functionality and hierarchical levels of target classification. The classification schemes are based on those established by the EC, GPCRDB, NuclearDB, and LGICDB. The ligands of the MDL Drug Data Report (MDDR) database serve as a reference data set of known pharmacologically active compounds. All ligands were annotated according to the schemes when attribution was possible based on the activity classification provided by the reference database. The purpose of the ligand-target classification schemes is to allow annotation-based searching of the ligand database. In addition, the biological sequence information of the target is directly linkable to the ligand, hereby allowing sequence similarity-based identification of ligands of next homologous receptors. Ligands of specified levels can easily be retrieved to serve as comprehensive reference sets for cheminformatics-based similarity searches and for design of target class focused compound libraries. Retrospective in silico screening experiments within the MDDR01.1 database, searching for structures binding to dopamine D2, all dopamine receptors and all amine-binding class A GPCRs using known dopamine D2 binding compounds as a reference set, have shown that such reference sets are in particular useful for the identification of ligands binding to receptors closely related to the reference system. The potential for ligand identification drops with increasing phylogenetic distance. The analysis of the focus of a tertiary amine based combinatorial library compared to known amine binding class A GPCRs, peptide binding class A GPCRs, and LGIC ligands constitutes a second application scenario which illustrates how the focus of a combinatorial library can be treated quantitatively. The provided annotation schemes, which bridge chem- and bioinformatics by linking ligands to sequences, are expected to be of key utility for further systematic chemogenomics exploration of previously well explored target families.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132896     DOI: 10.1021/ci010385k

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  12 in total

Review 1.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

2.  Quantifying the relationships among drug classes.

Authors:  Jérôme Hert; Michael J Keiser; John J Irwin; Tudor I Oprea; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2008-03-13       Impact factor: 4.956

Review 3.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

4.  Clustering: how much bias do we need?

Authors:  Tom Lorimer; Jenny Held; Ruedi Stoop
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-06-28       Impact factor: 4.226

Review 5.  Minimum information about a bioactive entity (MIABE).

Authors:  Sandra Orchard; Bissan Al-Lazikani; Steve Bryant; Dominic Clark; Elizabeth Calder; Ian Dix; Ola Engkvist; Mark Forster; Anna Gaulton; Michael Gilson; Robert Glen; Martin Grigorov; Kim Hammond-Kosack; Lee Harland; Andrew Hopkins; Christopher Larminie; Nick Lynch; Romeena K Mann; Peter Murray-Rust; Elena Lo Piparo; Christopher Southan; Christoph Steinbeck; David Wishart; Henning Hermjakob; John Overington; Janet Thornton
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

6.  Predicting new molecular targets for known drugs.

Authors:  Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian K Shoichet; Bryan L Roth
Journal:  Nature       Date:  2009-11-01       Impact factor: 49.962

Review 7.  The chemical basis of pharmacology.

Authors:  Michael J Keiser; John J Irwin; Brian K Shoichet
Journal:  Biochemistry       Date:  2010-11-12       Impact factor: 3.162

8.  Virtual screening of GPCRs: an in silico chemogenomics approach.

Authors:  Laurent Jacob; Brice Hoffmann; Véronique Stoven; Jean-Philippe Vert
Journal:  BMC Bioinformatics       Date:  2008-09-06       Impact factor: 3.169

9.  A mapping of drug space from the viewpoint of small molecule metabolism.

Authors:  James Corey Adams; Michael J Keiser; Li Basuino; Henry F Chambers; Deok-Sun Lee; Olaf G Wiest; Patricia C Babbitt
Journal:  PLoS Comput Biol       Date:  2009-08-21       Impact factor: 4.475

10.  SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data.

Authors:  Mats Eriksson; Ingemar Nilsson; Thierry Kogej; Christopher Southan; Martin Johansson; Christian Tyrchan; Sorel Muresan; Niklas Blomberg; Marcus Bjäreland
Journal:  Mol Inform       Date:  2012-08-07       Impact factor: 3.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.